GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

Jesse it's correct that mannosylation at Asn257 can serve to
enhance ADCC but assuming that is what Dr Meade was referring
to you are mistaken that CHO cannot enjoy that type of engineering. cf
http://www.freepatentsonline.com/y2007/0092521.html

>I did get the distinct impression from Dr. M. that the binding the NK cells is the most important action.

I don't doubt that at all. The citation mentions
another case where the apportionment of ADCC enhancement
between two alterations is controversial (fucose vs N-acetyl-glucosamine).

I am glad to be having this little chat because it reminds us
that our glycosylation characteristics are fundamental positives,
slide bullets in their own right, sometimes overshadowed
in the investment narrative.